ArticleJournal of translational medicine2025
Melittin inhibits NSCLC metastasis by targeting USP10 and promoting RNF20-mediated ubiquitination and degradation of PSMA7.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated isothermal shift assay and multi-omics identify melittin as a novel EGFR-targeting peptide to suppress NSCLC.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND AND
aimsNon-small cell lung cancer (NSCLC) accounts for > 80% of lung cancer cases, and its mortality is predominantly attributed to its metastatic nature. Therefore, developing novel therapeutic drugs and treatment methods to improve the prognosis of patients with NSCLC is critical. PURPOSE: This study examined the effect of Melittin (MEL) on NSCLC metastasis and explored the underlying regulatory mechanisms.
methodsThe effects of different doses of MEL on NSCLC cells was examined using Transwell and wound healing assays. RT-qPCR and western blotting were performed to assess the mRNA and protein expression of proteasome 20S subunit alpha 7 (PSMA7) and epithelial-mesenchymal transition-related genes such as E-cadherin and N-cadherin. A PSMA7 overexpressing lentiviral vector was constructed and transfected into HCC1833 and A549 cells to examine the inhibitory effect of MEL on NSCLC malignant progression. Proteomics analyses were performed to identify differentially expressed proteins in NSCLC cells following MEL treatment. The potential involvement of the ubiquitin degradation pathway was examined using cycloheximide and MG132. Co-immunoprecipitation (Co-IP) assays were performed to detect interactions between PSMA7, ubiquitin-specific peptidase (USP)-10, and ring finger protein (RNF)-20. An in vivo lung metastasis model was used to evaluate the effects of MEL on NSCLC metastasis.
resultsMEL treatment suppressed the malignant migration of NSCLC cells, as shown in Transwell and wound healing assays. MEL treatment also inhibited NSCLC lung metastasis in vivo. Proteomics analysis showed that MEL inhibited PSMA7 expression. Existing studies have shown that PSMA7 affects EMT process mainly by regulating the protein stability of key EMT factors. MEL downregulated EMT key factors, N-cadherin and upregulated E-cadherin, and it activated the ubiquitin degradation pathway, as shown by cycloheximide and MG132 treatments. Co-IP experiments showed that PSMA7 interacts with USP10 and RNF20. Molecular docking validated the interaction of MEL with USP10, confirming the involvement of the ubiquitin pathway in the effects of MEL on promoting the degradation of PSMA7. PSMA7 overexpression significantly reversed the inhibitory effect of MEL on NSCLC cell metastasis in vitro.
conclusionMEL suppresses the metastasis of NSCLC by targeting USP10 and promoting RNF20-mediated ubiquitination and degradation ofPSMA7.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.